Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan forecasts 2011 growth based on strong Q4 data

Allergan forecasts 2011 growth based on strong Q4 data

3rd February 2011

Allergan has expressed satisfaction with its growth in the fourth quarter of 2010, while providing a positive outlook on its 2011 sales prospects.

The company's total net product sales for the three months ending on December 31st 2010 came to $1.29 billion (795.28 million pounds), up by 6.9 percent year-on-year.

Growth was noted across both its specialty pharmaceuticals and medical device business units, with a strong performance highlighted for its leading Botox brand, which was recently approved in the US as a treatment for migraines.

For the 2011 full-year period, the company now expects total product net sales of between $5.02 billion and $5.22 billion.

David Pyott, Allergan's chairman of the board and chief executive officer, said: "In 2011, we look forward to marketing the new products and therapies approved in 2010, as well as investing in research and development to reload our pipeline."

This comes in the same week the company announced a new US-based collaboration with MAP Pharmaceuticals to develop a new migraine treatment option, Levadex.ADNFCR-8000103-ID-800383044-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.